Here, we’re trying to figure out who will be insured and to what extent, and the FDA approval process can hinder the rate of new drug development by biotechnology companies.
- It’s one-third less volatile than the S&P 500
- There’s exposure to England, Switzerland and France (France has the world’s third-largest health care budget; England provides free health care to all residents of the United Kingdom; health care is compulsory in Switzerland)
- Its five-year returns are within a few percentage points of the broader S&P 500, and with less risk
This fund sits far below its trend line (200-day moving average), so wait until it migrates back above before taking a look.
The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.